

**REMARKS**

Upon entry of the above amendment, claims 1-2, 4-8, 10-15, 17 and 19-35 will be pending in the captioned application. The claims have been amended to incorporate the hydrates, solvates, salts, hydrates of the salts and solvates of the salts of the compounds of formula 1. Specific basis for this amendment can be found in the paragraph spanning pages 7 and 8 of the specification. Further, various clerical errors have been corrected throughout the claims.

Neither the amendments to the claims, nor the newly introduced claims, add new matter within the meaning of 35 U.S.C. §132. Accordingly, the Examiner is respectfully requested to enter the above amendment before examination. If the Examiner has any questions regarding this submission, she is invited to telephone the undersigned attorney.

Respectfully submitted,  
**NATH & ASSOCIATES PLLC**

By: 

~~Gary M. Nath~~  
Registration No. 26,965  
Sheldon M. McGee  
Registration No. 50,454  
Customer No. 34375

Date: February 3, 2005  
**NATH & ASSOCIATES PLLC**  
1030 15<sup>th</sup> Street NW, 6<sup>th</sup> Floor  
Washington, D.C. 20005-1503  
(202)-775-8383  
GMN/SMM\PA.doc

10/523111


US Not yet assigned  
STERK  
Page 1 of 1

DT05 Rec'd OCT/PTO 03 FEB 2005

Appendix B

Abstract of the Disclosure

The compounds of a certain formula (1),



in which the given substituents have the meanings as given in the description, are novel effective PDE4 inhibitors.